



## BioNTech to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021

**MAINZ, GERMANY, January 5, 2021 (GLOBE NEWSWIRE)** —[BioNTech SE](#) (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 39<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021, at 10.50am ET.

A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at <https://biontech.de/>. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.

### About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit [www.BioNTech.de](http://www.BioNTech.de).

### BioNTech Contacts:

#### Media Relations

Jasmina Alatovic  
+49 89 62 81 75 46  
[Media@biontech.de](mailto:Media@biontech.de)

#### Investor Relations

Sylke Maas, Ph.D.  
+49 (0)6131 9084 1074  
[Investors@biontech.de](mailto:Investors@biontech.de)